Due to its action against iron overload, deferiprone has been considered as a potentially effective agent in Parkinson’s disease. However, an international RCT shows that the complaints are actually exacerbated by this medicine.
It is known that Parkinson’s disease is associated with an increased concentration of iron in the black matter of the brain. This may contribute to the pathophysiology of the condition. Deferiprone has been shown to be effective against iron overload and can cross the blood-brain barrier. That is why researchers conducted an RCT to…
The entire content of this article is only accessible to subscribers.
Read 3 articles FREE
Make an account. Free and without obligation.
I want 3x free
Always access to all NTvG publications?
Subscribe today!
Take the introductory subscription
€ 32.95 for 12 weeks!
I want to meet
Do you already have a subscription? login